Biology before Anatomy in Early Breast Cancer — Precisely the Point
Menée à partir d'échantillons tumoraux inclus en paraffine après prélèvement sur 10 253 patientes atteintes d'un cancer du sein HR+/HER2- sans envahissement des ganglions axillaires, cette étude évalue la performance d'un test, basé sur l'expression de 21 gènes, pour identifier les patientes ne nécessitant pas de chimiothérapie adjuvante
Building on a foundation of clinical and laboratory observations, translational research, broad collaborations, and global education, adjuvant therapy for early-stage breast cancer has been an effective public health intervention. Standardization and even a one-size-fits-all philosophy were supported by individual trials and the worldwide overviews that showed proportional reductions in risk with chemotherapy in particular. Because higher risk, identified anatomically on the basis of tumor size or the presence of ipsilateral axillary nodal metastases, was associated with greater absolute therapeutic benefit, many clinical groups set risk thresholds, defined as a tumor size of 1 cm in the greatest dimension or any involved nodes, to guide chemotherapy use.
New England Journal of Medicine , éditorial en libre accès, 2014